In clinical trials, multiplicity refers to which issue?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

In clinical trials, multiplicity refers to which issue?

Multiplicity is about the risk of finding a false positive when a trial tests more than one hypothesis or endpoint. When you have multiple endpoints or perform several analyses, the chance that at least one test looks significant just by random variation increases. That’s why the overall, or family-wise, type I error needs to be controlled across all tests to avoid overstating a treatment effect. To manage this, several pre-planned strategies are used. Hierarchical testing lets you order hypotheses so you only declare significance for downstream tests if earlier ones are significant. Bonferroni adjustment tightens the threshold for each test by dividing the overall alpha by the number of tests. Alpha-spending distributes the overall alpha across interim analyses or multiple looks at the data. Gatekeeping applies a structured sequence of hypotheses to preserve error control while permitting multiple endpoints to be tested in a principled way. Together, these approaches prevent the inflation of false positives while still allowing comprehensive assessment of a treatment’s effects. In contrast, focusing on a single primary endpoint minimizes multiplicity and isn’t about controlling error across many tests. Blinding helps reduce bias rather than address multiple comparisons. Post-hoc exploratory analyses are not the primary regulatory requirement for multiplicity and, if used, should be clearly labeled as exploratory with stringent caution about interpretation.

Multiplicity is about the risk of finding a false positive when a trial tests more than one hypothesis or endpoint. When you have multiple endpoints or perform several analyses, the chance that at least one test looks significant just by random variation increases. That’s why the overall, or family-wise, type I error needs to be controlled across all tests to avoid overstating a treatment effect.

To manage this, several pre-planned strategies are used. Hierarchical testing lets you order hypotheses so you only declare significance for downstream tests if earlier ones are significant. Bonferroni adjustment tightens the threshold for each test by dividing the overall alpha by the number of tests. Alpha-spending distributes the overall alpha across interim analyses or multiple looks at the data. Gatekeeping applies a structured sequence of hypotheses to preserve error control while permitting multiple endpoints to be tested in a principled way. Together, these approaches prevent the inflation of false positives while still allowing comprehensive assessment of a treatment’s effects.

In contrast, focusing on a single primary endpoint minimizes multiplicity and isn’t about controlling error across many tests. Blinding helps reduce bias rather than address multiple comparisons. Post-hoc exploratory analyses are not the primary regulatory requirement for multiplicity and, if used, should be clearly labeled as exploratory with stringent caution about interpretation.

More practice questions